Every new paper in 280 characters, with how strong the evidence is and what readers question about it. Free to read.
Geriatrics · Age Ageing · 2026-08-03
Secondary analysisn = 960
Lee et al. Antithrombotic strategy according to age in patients with atrial fibrillation and drug-eluting stents: a post hoc analysis of the ADAPT AF-DES randomised trialHaematology · Lancet Haematol · 2026-07-01
RCTn = 229
Brandão et al. Apixaban for the treatment of venous thromboembolic events in paediatric patients: an open-label, multicentre, randomised, controlled descriptive trialNeurology · JAMA Neurol · 2026-06-01
Secondary analysisn = 945
Ridha et al. Hypertension With High-Risk Features in Cryptogenic Stroke: An Exploratory Analysis of the ARCADIA Randomized Clinical TrialCardiology · J Am Heart Assoc · 2026-03-20
Secondary analysisn = 182
Aborkhees et al. Ex Vivo Effect of Apixaban on Hemostatic Biomarkers in Children With Heart Disease: A SAXOPHONE Trial SubstudyCardiology · N Engl J Med · 2026-03-12
RCTn = 2,760
Castellucci et al. Bleeding Risk with Apixaban vs. Rivaroxaban in Acute Venous ThromboembolismNeurology · Ann Neurol · 2026-02-25
Secondary analysisn = 1,015
Kamel et al. Apixaban Versus Aspirin and Risk of Hemorrhage in the ARCADIA TrialHaematology · Lancet Haematol · 2025-12-06
Secondary analysisn = 1,766
Mahé et al. Predictors of clinically relevant bleeding during extended anticoagulation for cancer-associated venous thromboembolism (API-CAT): a post-hoc analysis of a randomised, non-inferiority trialNeurology · Stroke · 2025-12-05
Secondary analysisn = 3,464
Gologorsky et al. Multiterritory Brain Infarcts, Anticoagulation, and Recurrence After Cryptogenic Stroke: A Subgroup Analysis of the ARCADIA Trial